Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570986 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 3
- Development phase
- 1,465
- Enrollment target
- 20
- Study locations
NCT00570986: Completed Phase 3 study of Plaque Psoriasis, sponsored by AbbVie (prior sponsor, Abbott).
NCT00570986 is a Phase 3 study of Plaque Psoriasis that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 1,465 participants, above the 383-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (283% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00570986, a Phase 3 study of Plaque Psoriasis, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,465 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL ABT-874
Study Locations (20)
California
- Site Reference ID/Investigator# 6591 - Bakersfield
- Site Reference ID/Investigator# 6710 - Fresno
- Site Reference ID/Investigator# 7885 - Irvine
- Site Reference ID/Investigator# 6872 - Los Angeles
- Site Reference ID/Investigator# 7669 - Oceanside
- Site Reference ID/Investigator# 6821 - San Diego
- Site Reference ID/Investigator# 6832 - San Diego
- Site Reference ID/Investigator# 7305 - San Diego
- Site Reference ID/Investigator# 7990 - San Francisco
- Site Reference ID/Investigator# 6711 - Santa Monica
- Site Reference ID/Investigator# 8139 - Torrance
- Site Reference ID/Investigator# 7167 - Vallejo
Alabama
- Site Reference ID/Investigator# 6579 - Birmingham
- Site Reference ID/Investigator# 6697 - Birmingham
- Site Reference ID/Investigator# 7015 - Huntsville
Arizona
- Site Reference ID/Investigator# 6728 - Scottsdale
- Site Reference ID/Investigator# 6584 - Tucson
Colorado
- Site Reference ID/Investigator# 7302 - Denver
- Site Reference ID/Investigator# 6921 - Longmont
Arkansas
- Site Reference ID/Investigator# 6696 - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,465 participants |
| Start Date | 2007-11 |
| Est. Completion | 2009-06 |
| Phase | Phase 3 |
What the finished NCT00570986 record still lists
NCT00570986 is an interventional study that assigns participants to a tested intervention. Its 1,465 participants enrollment target places it among the larger protocols in the corpus, above the 383-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (283% higher).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00570986 names 20 study sites across 5 states, led by California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT00570986 about?
NCT00570986 is a clinical study titled "A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis". The purpose of this study is to determine the safety and efficacy of 2 doses of ABT-874 versus placebo in the treatment of subjects with moderate to severe plaque psoriasis.
What is the current status of trial NCT00570986?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,465 participants. The study started on 2007-11. Estimated completion is 2009-06.
What conditions does trial NCT00570986 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT00570986?
The interventions under investigation include: Placebo (DRUG), ABT-874 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00570986?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00570986 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00570986's enrollment target sits among peer trials
1,465 4th of 45 higher than 42 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03936361 · 1,456 participants · Phase 3
Statins In Intracerbral Hemorrhage
- NCT06782347 · 1,454 participants · NA
Activating SilverSneakers Benefits for Seniors With Osteoarthritis
- NCT04566328 · 1,450 participants · Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- NCT05229341 · 1,450 participants · NA
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia